title: 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
abstract: Therapeutic subunit vaccines based on tumor-associated antigens (TAA) represent an attractive approach for the treatment of cancer. However, poor immunogenicity of TAAs requires potent adjuvants for therapeutic efficacy. We recently proposed the tumor necrosis factor family costimulatory ligands as potential adjuvants for therapeutic vaccines and, hence, generated a soluble form of 4-1BBL chimeric with streptavidin (SA-4-1BBL) that has pleiotropic effects on cells of innate, adaptive, and regulatory immunity. We herein tested whether these effects can translate into effective cancer immunotherapy when SA-4-1BBL was also used as a vehicle to deliver TAAs in vivo to dendritic cells (DCs) constitutively expressing the 4-1BB receptor. SA-4-1BBL was internalized by DCs upon receptor binding and immunization with biotinylated antigens conjugated to SA-4-1BBL resulted in increased antigen uptake and cross-presentation by DCs, leading to the generation of effective T-cell immune responses. Conjugate vaccines containing human papillomavirus 16 E7 oncoprotein or survivin as a self-TAA had potent therapeutic efficacy against TC-1 cervical and 3LL lung carcinoma tumors, respectively. Therapeutic efficacy of the vaccines was associated with increased CD4(+) T and CD8(+) T-cell effector and memory responses and higher intratumoral CD8(+) T effector/CD4(+)CD25(+)Foxp3(+) T regulatory cell ratio. Thus, potent pleiotropic immune functions of SA-4-1BBL combined with its ability to serve as a vehicle to increase the delivery of antigens to DCs in vivo endow this molecule with the potential to serve as an effective immunomodulatory component of therapeutic vaccines against cancer and chronic infections.
authors.affiliation: Department of Microbiology and Immunology, James Brown Cancer Center, Institute for Cellular Therapeutics, University of Louisville and ApoImmune, Inc, Louisville, Kentucky, USA.
authors.forename: Rajesh K
authors.initials: RK
authors.lastname: Sharma
authors.forename: Rich-Henry
authors.initials: RH
authors.lastname: Schabowsky
authors.forename: Abhishek K
authors.initials: AK
authors.lastname: Srivastava
authors.forename: Kutlu G
authors.initials: KG
authors.lastname: Elpek
authors.forename: Shravan
authors.initials: S
authors.lastname: Madireddi
authors.forename: Hong
authors.initials: H
authors.lastname: Zhao
authors.forename: Zhenping
authors.initials: Z
authors.lastname: Zhong
authors.forename: Robert W
authors.initials: RW
authors.lastname: Miller
authors.forename: Kathryn J
authors.initials: KJ
authors.lastname: Macleod
authors.forename: Esma S
authors.initials: ES
authors.lastname: Yolcu
authors.forename: Haval
authors.initials: H
authors.lastname: Shirwan
mesh_terms: D053330:4-1BB Ligand / Q000008:administration & dosage*; D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage*; D045142:Cross-Priming / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D051034:Inhibitor of Apoptosis Proteins; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D050725:Papillomavirus E7 Proteins / Q000378:metabolism; D012097:Repressor Proteins; D015996:Survival Rate; D000077022:Survivin; D013601:T-Lymphocytes / Q000276:immunology; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D053330:4-1BB Ligand; C117749:Birc5 protein, mouse; D019496:Cancer Vaccines; D007155:Immunologic Factors; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; D000077022:Survivin; C059731:oncogene protein E7, Human papillomavirus type 16
references.citation: Int Immunol. 2006 Feb;18(2):325-33
references.pmid: 16373363
references.citation: Nat Rev Immunol. 2007 Oct;7(10):790-802
references.pmid: 17853902
references.citation: Science. 2007 Jan 5;315(5808):107-11
references.pmid: 17204652
references.citation: J Clin Immunol. 2007 Jul;27(4):363-71
references.pmid: 17370119
references.citation: Nat Immunol. 2006 Feb;7(2):165-72
references.pmid: 16415871
references.citation: J Immunol. 2007 Aug 1;179(3):1427-30
references.pmid: 17641007
references.citation: J Immunol. 2009 Apr 1;182(7):4107-15
references.pmid: 19299708
references.citation: J Immunol. 2006 Aug 15;177(4):2276-84
references.pmid: 16887988
references.citation: Int J Cancer. 1998 Sep 25;78(1):41-5
references.pmid: 9724092
references.citation: Cell Mol Immunol. 2004 Feb;1(1):71-6
references.pmid: 16212924
references.citation: J Immunol. 2002 May 1;168(9):4262-7
references.pmid: 11970964
references.citation: Exp Mol Pathol. 2009 Jun;86(3):198-207
references.pmid: 19454266
references.citation: J Exp Med. 1998 Jun 1;187(11):1849-62
references.pmid: 9607925
references.citation: Vaccine. 2009 Dec 11;28(2):512-22
references.pmid: 19836479
references.citation: J Clin Invest. 2008 Jun;118(6):2098-110
references.pmid: 18497879
references.citation: Nat Immunol. 2005 Dec;6(12):1219-27
references.pmid: 16244650
references.citation: Science. 2005 Mar 11;307(5715):1630-4
references.pmid: 15761154
references.citation: J Immunol. 2007 May 15;178(10):6259-67
references.pmid: 17475854
references.citation: Transplantation. 2005 Jun 15;79(11):1492-7
references.pmid: 15940037
references.citation: Int Immunol. 2002 Mar;14(3):275-86
references.pmid: 11867564
references.citation: Eur J Immunol. 2008 Oct;38(10):2678-88
references.pmid: 18825741
references.citation: J Immunol. 2007 May 1;178(9):5429-33
references.pmid: 17442923
references.citation: Nat Immunol. 2004 Nov;5(11):1143-8
references.pmid: 15475958
references.citation: Methods Enzymol. 1990;184:51-67
references.pmid: 2388586
references.citation: J Immunol. 2001 May 1;166(9):5327-30
references.pmid: 11313367
references.citation: Clin Cancer Res. 2003 Nov 1;9(14):5091-100
references.pmid: 14613986
references.citation: J Exp Med. 2000 Dec 18;192(12):1685-96
references.pmid: 11120766
references.citation: J Clin Invest. 2002 Jun;109(12):1519-26
references.pmid: 12070296
references.citation: J Exp Med. 2004 Mar 15;199(6):815-24
references.pmid: 15024047
references.citation: J Immunol. 2008 Apr 15;180(8):5267-74
references.pmid: 18390707
references.citation: Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
references.pmid: 16344461
references.citation: Nat Med. 2004 Sep;10(9):942-9
references.pmid: 15322536
references.citation: J Immunol. 2001 May 1;166(9):5448-55
references.pmid: 11313382
references.citation: Diabetes. 2005 Dec;54(12):3395-401
references.pmid: 16306354
references.citation: Nat Rev Immunol. 2004 Jul;4(7):499-511
references.pmid: 15229469
references.citation: Cancer Res. 2009 May 15;69(10):4319-26
references.pmid: 19435920
references.citation: Nature. 2003 Feb 20;421(6925):852-6
references.pmid: 12594515
references.citation: J Clin Invest. 2002 Mar;109(5):651-9
references.pmid: 11877473
references.citation: J Exp Med. 1998 Dec 7;188(11):1977-83
references.pmid: 9841912
references.citation: J Exp Med. 2002 Dec 16;196(12):1627-38
references.pmid: 12486105
references.citation: Cancer Res. 2008 Jul 1;68(13):5206-15
references.pmid: 18593921
references.citation: J Biol Chem. 2005 Dec 16;280(50):41472-81
references.pmid: 16204238
references.citation: Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5561-6
references.pmid: 11929985
references.citation: Annu Rev Immunol. 2005;23:23-68
references.pmid: 15771565
references.citation: Nat Rev Immunol. 2003 Aug;3(8):630-41
references.pmid: 12974478
references.citation: J Immunol. 2007 Dec 1;179(11):7295-304
references.pmid: 18025172